

Could you please provide answers to the following questions?

Q1. Please provide the number of patients treated (for any condition) in the last 4 months with:

- **Ajovy (fremanezumab)**
- **Aimovig (erenumab)**
- **Emgality (galcanezumab)**

For the period July 2020 – October 2020 the quantity of Erunumab SC Injection 70mg dispensed was 114.

Q2. How many of these patients were treated as part of a free or nominal charge scheme with:

- **Ajovy (fremanezumab)**
- **Aimovig (erenumab)**
- **Emgality (galcanezumab)**

As above

Q3. How many patients have you treated in the last 4 months for:

- **Any type of migraine**
- **Chronic migraine (15+ headache days per month).**
- **Episodic migraine (4+ headache days per month)**

Information not available

Q4. Please provide the number of migraine patients treated in the last 4 months with Botulinum Toxin (i.e. Botox, Dysport, Xeomin)

Whilst we cannot provide you with definitive patient numbers we can provide the number of units issued during the period:

Botulinum Toxin Type A

(Botox) Injection 100units x 5 vial

(Botox) Injection 200units x 38 vials

(Xeomin) 50units x 14 vials

(Xeomin) 100units x 13 vials

(Xeomin) 200units x 13 vials

(Dysport) 500units x 11 vials

(Dysport) 300units x 7 units

Q5. In case you do not treat chronic or episodic migraine, can you please tell us which hospital or trust you refer these patients to?

Not applicable